December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

145.53 +8.21 (+5.98%)
Streaming Delayed Price Updated: 12:03 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Monday's session: top gainers and losers ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Via ACCESSWIRE
News headline image
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Top movers in Monday's pre-market session ↗
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Why Is Protagonist Therapeutics Stock Trading Higher On Monday? ↗
Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints. 
Via Benzinga
News headline image
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out ↗
The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment. 
Via Investor's Business Daily
News headline image
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
Via ACCESS Newswire
News headline image
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Via ACCESS Newswire
News headline image
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer ↗
Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety results, earning Protagonist $25 million. 
Via Benzinga
News headline image
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) is a candidate for growth investors. Here's why. ↗
A fundamental analysis of (NASDAQ:PTGX): PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing high EPS and FCF growth while beating expectations 
Via Chartmill
News headline image
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESSWIRE
News headline image
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Via ACCESSWIRE
News headline image
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
Via ACCESSWIRE
News headline image
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
Via ACCESSWIRE
News headline image
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Via ACCESSWIRE
News headline image
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
Via ACCESSWIRE
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Via ACCESSWIRE
News headline image
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines ↗
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. 
Via Benzinga
News headline image
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Via ACCESSWIRE
News headline image
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.